-
A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.
You can participate in this study if you are diagnosed with stage 3 or stage 4 skin melanoma. The purpose of this study is to ...Phase
Interventional
Accepts Healthy Volunteer
